News

Net profit of Glaxosmithkline Pharmaceuticals rose 5.70% to Rs 277.86 crore in the quarter ended March 2026 as against Rs 262.87 crore during the previous quarter ended March 2025. Sales rose 2.15% to Rs 995.30 crore in the quarter ended March 2026 as against Rs 974.37 crore during the previous quarter ended March 2025.For the full year,net profit rose 11.69% to Rs 1035.98 crore in the year ended March 2026 as against Rs 927.58 crore during the previous year ended March 2025. Sales rose 1.93% to Rs 3821.67 crore in the year ended March 2026 as against Rs 3749.21 crore during the previous year ended March 2025. ParticularsQuarter EndedYear EndedMar. 2026Mar. 2025% Var.Mar. 2026Mar. 2025% Var. Sales995.30974.37 2 3821.673749.21 2 OPM %35.2634.20 -34.2631.40 - PBDT386.27373.29 3 1451.831321.98 10 PBT373.10358.57 4 1385.391255.19 10 NP277.86262.87 6 1035.98927.58 12 Powered by Capital Market - Live News

GlaxoSmithKline Pharmaceuticals announced that the 101th Annual General Meeting(AGM) of the company will be held on 30 June 2026.

GlaxoSmithKline Pharmaceuticals announced that the Board of Directors of the Company at its meeting held on 13 May 2026, has recommended a Final Dividend of Rs.57 per share (i.e.570%), subject to the approval of the shareholders.

GlaxoSmithKline Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 13 May 2026.

Glaxosmithkline Pharmaceuticals announced that Vinay Subramanian, Commercial Head - Oncology would be part of leadership team effective 20 April 2026 based out of Mumbai, and he would be part of senior Management Personnel of the Company effective the said date. Vinay brings with him over 24 years of experience in the Pharmaceuticals, Life Science. Healthcare Devices, and Medical Technology sectors. Prior to joining GSK. he served as the India Enabling leader - Enterprise & Neighboring Countries at Roche Products India Pvt ltd. where he was responsible for the immunotherapy portfolio and was part of their leadership team.